Abstract: Described herein is the use of a cyclotriphosphazene core substituted with at least three amino-cyclic carbon groups used as a charge-enhancing additive in a thermoplastic resin. Such compositions may be used in filtering applications.

Abstract: Described herein is a thermoplastic core-sheath fiber. The thermoplastic core-sheath fiber comprises a core having a coextensive sheath layer disposed thereon, wherein the core comprises a first polymeric resin and an electrostatic charge enhancing additive, and the sheath layer comprising a second polymeric resin, with the proviso that if the second polymeric resin comprises poly(4-methyl-1-pentene), then the second polymeric resin does not comprise 100 wt % of poly(4-methyl-1-pentene). These thermoplastic core-sheath fibers can be used in filtering applications.

Abstract: A pleated multilayer air filter assembly including a primary filtration layer and a prefilter layer that are bonded to each other and are co-pleated with each other. The primary filtration layer includes meltblown electret fibers. The prefilter layer includes meltspun, spunbonded electret fibers that comprise a radially outer surface comprising polymethylpentene. The ratio of Effective Fiber Diameter of the fibers of the primary filtration layer to Effective Fiber Diameter of the fibers of the primary filtration layer is at least 1.5.

Abstract: A thermoplastic core-sheath fiber comprises: a polymer fiber core having a coextensive sheath layer disposed thereon, and an electrostatic charge enhancing additive. The sheath layer may comprise poly(4-methyl-1-pentene) and the fiber core and the sheath layer have different compositions. At least one of the fiber core or the sheath layer comprises an electret charge. A nonwoven fibrous web comprising the core-sheath fibers and a respirator including the nonwoven fibrous web are also disclosed.

Abstract: A filter assembly comprises an air filter medium and a prefilter medium. The prefilter medium comprises a second nonwoven fibrous web comprising poly(4-methylpentene) and an electrostatic charging additive and has a second electret charge. The filter assembly is configured such that air passing through the prefilter is directed through the air filter medium. A respirator includes the filter assembly. A prefilter assembly comprises a third nonwoven fibrous web retained by a prefilter frame. The third nonwoven fibrous web comprises: core-sheath fiber comprising a fiber core having a poly(4-methylpentene) sheath layer disposed thereon; and an electrostatic charging additive, wherein the electrostatic charging additive is contained in at least one of the fiber core or the sheath layer. The third nonwoven fibrous web has a third electret charge.

Abstract: A method of making active pharmaceutical ingredient particles with surface-modified nanoparticles deposited on the particles' surfaces, the method comprising: providing a plurality of media particles having surfaces with the surface-modified nanoparticles deposited on the surfaces; mixing the plurality of media particles with the active ingredient particles, both of which are in dry form, to provide active ingredient particles having surfaces with the surface-modified nanoparticles deposited on the surfaces; and separating the plurality of media particles from the active ingredient particles having surfaces with the surface-modified nanoparticles deposited on the surfaces is disclosed.

Abstract: A method of treating a patient with a microneedle array having an active agent disposed on at least a portion of one or more of the microneedles, wherein the array with active agent is characterized by a first optical response when probed with a selected incident light spectrum. The array with active agent is applied to a skin surface, optionally allowed to remain on the skin surface for a specified time, and removed. The used array is probed with the selected incident light spectrum, a second optical response is sensed, and the difference between the first optical response and the second optical response is determined and compared to a predetermined threshold value.

Abstract: Thermotropic liquid crystalline polymer microneedles (100) are described.

Abstract: A method of making active pharmaceutical ingredient particles with surface-modified nanoparticles deposited on the particles' surfaces, the method comprising: providing a plurality of media particles having surfaces with the surface-modified nanoparticles deposited on the surfaces; mixing the plurality of media particles with the active ingredient particles, both of which are in dry form, to provide active ingredient particles having surfaces with the surface-modified nanoparticles deposited on the surfaces; and separating the plurality of media particles from the active ingredient particles having surfaces with the surface-modified nanoparticles deposited on the surfaces is disclosed.

Abstract: A method of coating a microneedle array comprising: providing a microneedle array having a substrate and at least one needle; providing a removable masking layer on the microneedle array such that the substrate is at least partially covered by the masking layer and the at least one needle remains at least partially exposed; and applying a coating material to at least a portion of the exposed portion of the microneedle array.

Abstract: The invention comprises a medicinal aerosol composition comprising a propellant, an excipient comprising a functionalized polyethyleneglycol, and a drug. The invention also comprises particulate medicinal compositions comprising particles with a mean mass aerodynamic diameter of less than about 10 microns that incorporate an excipient comprising a functionalized polyethyleneglycol.

Abstract: Methods, compounds, and medicinal formulations utilizing biocompatible polymers for delivery of a drug, particularly for solubilizing, stabilizing and/or providing sustained release of drug from topical, implantable, and inhalation systems. Many of the methods, compounds, and medicinal formulations are particularly suitable for oral and/or nasal inhalation and use polymers of the formula —[X—R1—C(O)]— wherein each R1 is an independently selected organic group that links the —X— group to the carbonyl group, and each X is independently oxygen, sulfur, or catenary nitrogen.

Abstract: A method of treating a patient with a microneedle array having an active agent disposed on at least a portion of one or more of the microneedles, wherein the array with active agent is characterized by a first optical response when probed with a selected incident light spectrum. The array with active agent is applied to a skin surface, optionally allowed to remain on the skin surface for a specified time, and removed. The used array is probed with the selected incident light spectrum, a second optical response is sensed, and the difference between the first optical response and the second optical response is determined and compared to a predetermined threshold value.

Abstract: A microneedle array having a substrate and a plurality of microneedles extending out from the substrate with a multi-phase matrix coating on at least a portion of the microneedle surface of the microneedle array. The multi-phase matrix coating comprises an active substance and has a first solid phase and a liquid phase. The first solid phase comprises a water-soluble polymer. Also, a method of providing an active substance- containing matrix coating on a microneedle array in which a water-soluble polymer is applied to the microneedle surface of the array to form a dried coating of water-soluble polymer. A coating solution comprising an active substance, a liquid capable of phase separating from the water-soluble polymer, and a carrier fluid is prepared and applied to the dried coating of water-soluble polymer. At least a portion of the carrier fluid is removed from the array.

Abstract: A method of coating a microneedle array comprising: providing a microneedle array having a substrate and at least one needle; providing a removable masking layer on the microneedle array such that the substrate is at least partially covered by the masking layer and the at least one needle remains at least partially exposed; and applying a coating material to at least a portion of the exposed portion of the microneedle array.

Abstract: The invention comprises a medicinal aerosol composition comprising a propellant, an excipient comprising an acid or amine end-group and at least one and no more than two amide and/or ester functional groups, and a drug. The invention also comprises particulate medicinal compositions comprising particles with a mean mass aerodynamic diameter of less than about 10 microns that incorporate an excipient containing an acid or amine end-group and at least one and no more than two amide and/or ester functional groups.

Abstract: A transdermal drug delivery device involving a macromonomer-containing acrylate or methacrylate copolymer, a softener, and a drug. Also a pressure sensitive skin adhesive involving a macromonomer containing acrylate or methacrylate copolymer and a softener.

Abstract: The present invention relates to a pressure sensitive adhesive composition comprising a copolymer comprising pyrrolidonoethyl acrylate or pyrrolidonoethyl methacrylate. This composition may be used as part of a transdermal drug delivery device.

Abstract: The invention comprises a medicinal aerosol composition comprising a propellant, an excipient comprising a functionalized polyethyleneglycol, and a drug. The invention also comprises particulate medicinal compositions comprising particles with a mean mass aerodynamic diameter of less than about 10 microns that incorporate an excipient comprising a functionalized polyethyleneglycol.

Abstract: The invention comprises a medicinal aerosol composition comprising a propellant, an excipient comprising an acid or amine end-group and at least one and no more than two amide and/or ester functional groups, and a drug. The invention also comprises particulate medicinal compositions comprising particles with a mean mass aerodynamic diameter of less than about 10 microns that incorporate an excipient containing an acid or amine end-group and at least one and no more than two amide and/or ester functional groups.